

**Comparison of COVID-19 outcomes among shielded and non-shielded populations:
A general population cohort study of 1.3 million**

Bhautesh D Jani,* Frederick K Ho,* David J Lowe, Sean MacBride-Stewart, Frances S Mair,
Jill P Pell

*Joint-first author

Bhautesh D Jani PhD
Clinical Senior Lecturer in General Practice and Primary Care
Institute of Health and Wellbeing, University of Glasgow,
Glasgow G12 9LX, UK
Bhautesh.jani@glasgow.ac.uk

Frederick K Ho PhD
Research Associate
Institute of Health and Wellbeing, University of Glasgow
Glasgow, G12 8RZ, UK
Frederick.Ho@glasgow.ac.uk

David J Lowe MSc
Consultant in Emergency Medicine,
Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde,
Glasgow, G52 4TF, UK
David.lowe@nhs.net

Sean MacBride-Stewart PhD
Lead Pharmacist (Medicines Management Resources)
Pharmacy Services
NHS Greater Glasgow and Clyde, G76 7AT, UK
Sean.MacBride-Stewart@ggc.scot.nhs.uk

Frances S Mair MD
Norie Miller Professor of General Practice
Institute of Health and Wellbeing, University of Glasgow,
Glasgow G12 9LX, UK
Frances.mair@glasgow.ac.uk

Jill P Pell MD
Henry Mechan Professor of Public Health
Institute of Health and Wellbeing, University of Glasgow,
Glasgow, G12 8RZ, UK
Jill.pell@glasgow.ac.uk

Supplementary Table 1. Criteria for high risk and moderate risk categories


High Risk	Moderate Risk
Severe respiratory disease: • severe COPD • severe asthma (high-dose steroids) • cystic fibrosis Specific cancers: • Lung cancer plus radical radiotherapy or active chemotherapy • Blood or bone marrow cancers • Bone marrow or stem cell transplant ○ in last 6 months, or ○ still taking immunosuppressants • immunotherapy or continuing antibody treatment • protein kinase inhibitors or PARP inhibitors Pregnant with significant heart disease Immunosuppressive therapy Solid organ transplant Relevant rare diseases and inborn errors of metabolism (e.g. SCID, homozygous sickle cell) Renal dialysis	Chronic respiratory disease: • COPD • asthma • emphysema • bronchitis Other chronic conditions • heart disease/hypertension • diabetes • kidney disease • liver disease • neurological conditions Pregnant Weakened immune system due to: • Medical condition • Medication (e.g. oral steroids, chemotherapy) BMI ≥ 40 kg/m² ≥ 70 years of age

Supplementary Table 2. Population attributable fractions for risk categories and risk criteria and COVID-19 outcomes

	Confirmed COVID-19		COVID-19 hospitalisation		COVID-19 ICU admission		COVID-19 Death	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
<i>Moderate</i>								
<i>Overall</i>	41.22	40.66-41.81	61.33	60.72-61.97	20.78	15.36-27.07	75.27	75.06-75.48
Chronic respiratory disease	3.50	3.22-3.75	5.08	4.78-5.36	0.90	-2.65-4.78	2.23	2.01-2.51
Heart disease	4.74	4.63-4.84	7.98	7.83-8.12	1.74	0.42-3.31	6.19	6.1-6.27
Hypertension	10.18	9.97-10.38	17.20	16.95-17.44	8.93	6.52-11.48	12.00	11.83-12.18
Diabetes	5.22	5.09-5.34	7.95	7.79-8.09	9.79	8.51-10.95	4.98	4.9-5.08
Weakened immune system	0.14	0.13-0.16	0.23	0.22-0.25	-	-	0.34	0.32-0.36
≥70 years of age	17.45	17.26-17.65	22.90	22.61-23.22	-	-	49.53	49.17-49.91
<i>High</i>								
<i>Overall</i>	8.58	8.4-8.75	15.45	15.13-15.75	4.91	3.7-6.3	13.38	13.2-13.54
Severe respiratory disease	0.39	0.37-0.43	5.74	5.57-5.9	-	-	0.56	0.53-0.59
Specific cancers	3.37	3.26-3.48	1.69	1.63-1.76	-	-	6.90	6.78-7
Immunosuppressive therapy	0.89	0.84-0.93	1.84	1.77-1.92	-	-	1.29	1.24-1.34
Solid organ transplant	1.41	1.36-1.48	0.77	0.72-0.82	-	-	2.00	1.95-2.07
Rare diseases and IEM	0.84	0.79-0.89	1.32	1.26-1.39	-	-	1.69	1.61-1.78
Renal dialysis	1.67	1.61-1.74	4.08	3.97-4.21	-	-	0.93	0.9-0.97

CI confidence interval; IEM inborn errors of metabolism

Supplementary Figure 1. Cumulative population attributable fractions (lines) and population prevalence (bars) for individual risk criteria



Brown – high risk criteria

Pale orange – medium risk criteria